Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
All content for The Long Run with Luke Timmerman is the property of Timmerman Report and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
The Long Run with Luke Timmerman
1 hour 2 minutes 56 seconds
8 months ago
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
The Long Run with Luke Timmerman
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
